DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...

Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.

But when the retina is damaged, vision can slowly become blurred, distorted or permanently lost, often before a person even ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ...

A phase III trial found that the sustained-release VEGF inhibitor implant OTX-TKI preserved visual acuity and retinal anatomy in wet age-related macular degeneration better than standard aflibercept ...

"The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President, CEO & Director Jay ...

A local retinal surgeon and ophthalmology professor will speak about age-related macular degeneration during a free webinar ...

Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 -Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients ...

Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dosefor treatment of wetage-related macular ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association ...